Hikma Eyes Return To Growth After Further Cutting Generics Forecasts
Injectables And Branded Increases Offset 18% Sales Slide For Generics Unit In First Half
Hikma has once again downgraded its expectations for its generics business in 2022 as it revealed a first-half drop of 18% in sales for the unit. However, injectables and branded increases helped to offset the decline, while the company maintained that generics growth was on the horizon in 2023.
